You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

CLINICAL TRIALS PROFILE FOR ACTOPLUS MET XR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ACTOPLUS MET XR

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01800227 ↗ Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fasting Conditions Completed Torrent Pharmaceuticals Limited Phase 1 1969-12-31 Objective: subjects to compare the single dose bioavailability of Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets 15 mg/850 mg and Actoplus Met® (pioglitazone hydrochloride and metformin hydrochloride) Tablets 15 mg/850 mg of Takeda Pharmaceuticals America, Inc. USA. Dosing periods of studies were separated by a washout period of 14 days. Study Design: Randomized, Two-Way Crossover, Single-Dose, and Open-Label
NCT01800240 ↗ Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fed Conditions Completed Torrent Pharmaceuticals Limited Phase 1 1969-12-31 Objective: subjects to compare the single dose bioavailability of Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets 15 mg/850 mg and Actoplus Met® (pioglitazone hydrochloride and metformin hydrochloride) Tablets 15 mg/850 mg of Takeda Pharmaceuticals America, Inc. USA. Dosing periods of studies were separated by a washout period of 14 days. Study Design: Randomized, Two-Way Crossover, Single-Dose, and Open-Label
NCT02917629 ↗ ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment Terminated National Cancer Institute (NCI) Phase 2 2017-08-14 This randomized phase IIb trial studies how well ACTOplus met XR works in treating in patients with stage I-IV oral cavity or oropharynx cancer that are undergoing definitive treatment. Chemoprevention is the use of drugs to keep oral cavity or oropharynx cancer from forming or coming back. The use of ACTOplus met XR may slow disease progression in patients with oral cavity or oropharynx cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ACTOPLUS MET XR

Condition Name

Condition Name for ACTOPLUS MET XR
Intervention Trials
Healthy 2
Stage II Oropharyngeal Squamous Cell Carcinoma 1
Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 1
Oral Cavity Neoplasm 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ACTOPLUS MET XR
Intervention Trials
Oropharyngeal Neoplasms 1
Neoplasms 1
Mouth Neoplasms 1
Carcinoma, Squamous Cell 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ACTOPLUS MET XR

Trials by Country

Trials by Country for ACTOPLUS MET XR
Location Trials
United States 4
India 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ACTOPLUS MET XR
Location Trials
Wisconsin 1
New York 1
Minnesota 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ACTOPLUS MET XR

Clinical Trial Phase

Clinical Trial Phase for ACTOPLUS MET XR
Clinical Trial Phase Trials
Phase 2 1
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ACTOPLUS MET XR
Clinical Trial Phase Trials
Completed 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ACTOPLUS MET XR

Sponsor Name

Sponsor Name for ACTOPLUS MET XR
Sponsor Trials
Torrent Pharmaceuticals Limited 2
National Cancer Institute (NCI) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ACTOPLUS MET XR
Sponsor Trials
Industry 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.